JP Morgan Maintains Overweight on Arrowhead Pharma, Raises Price Target to $95

Benzinga Newsdesk www.benzinga.com Positive 75.8%

Neg 0% Neu 0% Pos 75.8%

JP Morgan analyst Brian Cheng maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $88 to $95.